Capital Management Associates NY acquired a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 6,000 shares of the exchange traded fund’s stock, valued at approximately $732,000.
Several other hedge funds also recently added to or reduced their stakes in XBI. JPMorgan Chase & Co. raised its position in SPDR S&P Biotech ETF by 27.3% in the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after purchasing an additional 2,900,633 shares during the period. Assetmark Inc. raised its position in SPDR S&P Biotech ETF by 1,042,265.6% in the fourth quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock valued at $77,528,000 after purchasing an additional 635,782 shares during the period. Greenwoods Asset Management Hong Kong Ltd. purchased a new position in SPDR S&P Biotech ETF in the third quarter valued at about $55,613,000. Ameriprise Financial Inc. raised its position in SPDR S&P Biotech ETF by 123.0% in the second quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock valued at $72,542,000 after purchasing an additional 481,408 shares during the period. Finally, Main Street Research LLC purchased a new position in SPDR S&P Biotech ETF in the fourth quarter valued at about $43,959,000.
SPDR S&P Biotech ETF Price Performance
NYSEARCA:XBI opened at $131.66 on Tuesday. The business’s 50-day moving average is $130.00 and its two-hundred day moving average is $125.32. SPDR S&P Biotech ETF has a 12 month low of $78.00 and a 12 month high of $139.19. The firm has a market capitalization of $8.40 billion, a PE ratio of 11.47 and a beta of 0.85.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
